BC has been the topic of a number of recent analyst reports. Citigroup lifted their target price on Brunswick from $92.00 to $101.00 and gave the company a “buy” rating in a research report on ...
New Brunswick's Department of Health is missing ... only 44 per cent received treatment within the Department of Health's 14-day target. How often that target was met also differed by health ...
A number of brokerages recently commented on BC. Benchmark reaffirmed a “buy” rating and issued a $100.00 price target on shares of Brunswick in a research note on Friday, October 25th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback